Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIASIT-M
- Development stage
- Approved
- Lead developer
- Omnica Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DIASIT-M is a fixed-dose combination antidiabetic medication developed and manufactured by Omnica Laboratories, a WHO-GMP certified pharmaceutical company based in Nepal. It combines sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with metformin, a biguanide. Sitagliptin functions by inhibiting the DPP-4 enzyme, which slows the inactivation of incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. Metformin works primarily by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. DIASIT-M is indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
- Brand names
- DIASIT-M
- Other names
- sitagliptin + metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on DIASIT-M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIASIT-M.